Clinical Trial

The COSMYC Trial (COmbined Suppression of MYC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-03; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2025-09-11
Trial Details
NCT Number NCT06922318
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Zenith Epigenetics, National Cancer Institute (NCI)
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 50 participants
Start Date 2025-08-19
Primary Completion 2031-08-30 (estimated)
Study Completion 2031-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-18